Have any questions?
info@mpncancerconnection.org

Our Mission
Clinical Trial Finder
Blog
About
- Our team
- Info
- David Wallace Bio
  David Wallace
  
  Founder & CEO of MPN Cancer Connection and PV Reporter | Patient Advocate
  When David was diagnosed with PV in 2009, at the age of 47, he soon learned there was limited and often conflicting information available on Myeloproliferative Neoplasms (MPNs). He also realized early on in his diagnosis, the importance of advocating for himself to best manage his polycythemia vera (PV). David was grateful for the early support and guidance of fellow MPN patients on his journey and wanted a way to give back to the MPN community. With a professional background in business administration and sociology, David has a passion for finding solutions and helping others. In 2013, David used his skill set to create PV Reporter, a comprehensive patient-focused website for MPNs. David refers to his site as a hub for patients to begin to research their cancer. Whether a patient, caregiver or healthcare provider, PV Reporter offers visitors a wealth of educational resources, patient stories, articles, and the latest news on the treatment for MPNs, helping MPN patients and their caregivers stay informed, connected and empowered. In 2015, along with the help of others, David founded a non-profit MPN Cancer Connection (MPN-CC), a patient-led 501©3 formed to create awareness that MPN patients are “cancer patients” and should have complete access to local and national programs and benefits. David’s philosophy is to educate patients to become their own advocates so that they can make informed decisions on their treatment. David’s dedication to the MPN community is further evidenced through his work and awards:
  - Selected to endorse 2018 NCCN guidelines for MPN patients by MPN Cancer Connection
  - Selected to represent the United States as a patient advocate by MPNs Advocate Network International Conference 2016-2019
  - Recipient of MPN Hero Award 2016
  - Published in MD Anderson Cancer Center MPN Focus Newsletter Fall 2016
  - Appearance on “The Doctors” TV show in 2015 to promote MPN awareness
  - Awarded Press Credentials for American Society of Hematology Conference 2014-2019
  - Contributor to Patient Power MPN educational videos
  David lives in Charlotte, North Carolina. When he’s not working, David enjoys spending time with family, listening to live music, attending outdoor festivals, watching the Carolina Panthers, riding his motorcycle, traveling and of course having his beloved Aussiedoodle Bailey by his side.
Resources
Our Vision
- Donate
Contact

Understanding the JAK2 Mutation

Frequency of MPN in Korea

Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea

August 28, 2016

ropeginterferon

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

September 20, 2016

Understanding the JAK2 Mutation

Published by mpncancer at August 30, 2016

Categories

Tags

Understanding the JAK2 mutation

THE STORY OF JAK2

Four teams race to find the mysterious cause of a group of blood cancers.

JAK2 MUTATIONS AT A GLANCE

Involved in: blood cancers and disorders including polycythemia vera, primary myelofibrosis, thrombocythemia, leukemia.

Testing requires: a blood draw. Bone marrow samples occasionally used.

Prognosis: Patients with a JAK2 mutation have a lower survival rate and higher rate of blood clots when compared to patients with a CALR mutation.

Treatment: Ruxolitinib may improve quality of life in patients with a JAK2 mutation.

This Gene is also known as: JTK10, THCYT3

Click the link below for the complete article…

[contentcards url=”https://www.cureforward.com/stories/gene-stories/jak2/” target=”_blank”]

Related

mpncancer

Comments are closed.

Malcare WordPress Security